The Open Science Forum features monthly talks from scientists from NIH-funded Antiviral Drug Discovery (AViDD) Centers who elect to provide updates on target priorities, advertise available resources and reagents, disclose chemical matter (such as hits, leads, and chemical tool compounds) and associated antiviral data, share findings regarding in vivo efficacy models, discuss downstream development and translation models, and share ideas.
Talks will be public, recorded, and shared online along with links to relevant resources and reagents for the benefit of other AViDD Centers and the global antiviral drug discovery community.
An unrecorded discussion with the speakers follows each pair of talks for those that wish to discuss the science behind the work more deeply.
Presentation
Moderator: Karla Kirkegaard, Stanford University
| Innovation in clinical research for infectious diseases through Controlled Human Infection Models Ingrid de Visser-Kamerling and Jeroen Kruter, INFECTA |
| Open-science discovery of DNDI-6510, a compound that addresses genotoxic and metabolic liabilities of the COVID Moonshot SARS-CoV-2 Mpro lead inhibitor Annette von Delft, Centre For Medicines Discovery and Peter Sjo, Head of Drug Discovery Programme, DNDi |
